-
1مراجعة
المؤلفون: Adili, Ali, Ghoreishizadeh, Shadi, Shomali, Navid, Hasani, Sadegh Abaei, Sharafi, Faezeh, Alesaeidi, Samira, Kahrizi, Mohammad Saeed
مصطلحات موضوعية: Hepatocellular carcinoma, T-Cells, Blockade, Ctla-4, Immune checkpoint inhibitors, Combination therapy, Acquired-Resistance, Tigit, Antitumor, Tim-3, Lag-3, Tremelimumab, Mechanisms
العلاقة: Cancer Cell International; Diğer; https://hdl.handle.net/11454/77817Test; https://doi.org/10.1186/s12935-022-02682-zTest; Kahrizi, Mohammad saeed/0000-0002-8076-2413; 22
-
2مراجعة
المؤلفون: Sharafi, Faezeh, Hasani, Sadegh Abaei, Alesaeidi, Samira, Kahrizi, Mohammad Saeed, Adili, Ali, Ghoreishizadeh, Shadi, Shomali, Navid
مصطلحات موضوعية: Immune checkpoint inhibitors, Hepatocellular carcinoma, Combination therapy, Acquired-Resistance, T-Cells, Blockade, Ctla-4, Tigit, Antitumor, Tim-3, Lag-3, Tremelimumab, Mechanisms
العلاقة: Cancer Cell International; Diğer; https://doi.org/10.1186/s12935-022-02682-zTest; https://hdl.handle.net/11454/85121Test; 22; WOS:000843527300004; 2-s2.0-85136994397
-
3مراجعة
المؤلفون: Sharafi, Faezeh, Hasani, Sadegh Abaei, Alesaeidi, Samira, Kahrizi, Mohammad Saeed, Adili, Ali, Ghoreishizadeh, Shadi, Shomali, Navid
مصطلحات موضوعية: Immune checkpoint inhibitors, Hepatocellular carcinoma, Combination therapy, Acquired-Resistance, T-Cells, Blockade, Ctla-4, Tigit, Antitumor, Tim-3, Lag-3, Tremelimumab, Mechanisms
العلاقة: Cancer Cell International; Diğer; https://doi.org/10.1186/s12935-022-02682-zTest; https://hdl.handle.net/11454/77817Test; 22; WOS:000843527300004; 2-s2.0-85136994397